FITC标记的低密度脂蛋白受体的诱导降解蛋白抗体
产品名称： FITC标记的低密度脂蛋白受体的诱导降解蛋白抗体
英文名称： Anti-MYLIP/FITC
产品编号： HZ-9674R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-MYLIP/FITC Conjugated antibody
FITC标记的低密度脂蛋白受体的诱导降解蛋白抗体
| 产品编号 | bs-9674R-FITC |
| 英文名称 | Anti-MYLIP/FITC |
| 中文名称 | FITC标记的低密度脂蛋白受体的诱导降解蛋白抗体 |
| 别 名 | BZF1; E3 ubiquitin protein ligase MYLIP; E3 ubiquitin-protein ligase MYLIP; Idol; Inducible degrader of the LDL-receptor; Idol; MIR; MYLIP; MYLIP_HUMAN; Myosin regulatory light chain interacting protein. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 心血管 细胞生物 信号转导 细胞周期蛋白 细胞骨架 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 49kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MYLIP |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. Function: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. Subunit: Interacts with myosin regulatory light chain (MRLC) and TMEM4. Subcellular Location: Cytoplasm. Tissue Specificity: Ubiquitously expressed. Post-translational modifications: Autoubiquitinated. Similarity: Contains 1 FERM domain. Contains 1 RING-type zinc finger. Database links: Entrez Gene: 29116 Human Entrez Gene: 218203 Mouse Omim: 610082 Human SwissProt: Q8WY64 Human SwissProt: Q8BM54 Mouse Unigene: 484738 Human Unigene: 212855 Mouse Unigene: 481228 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
E3泛素蛋白连接酶介导肌球蛋白调节轻链（MRLC）、LDLR、VLDLR和LRP8的泛素化和随后的蛋白酶体降解。蛋白酶体降解MRLC通过抑制类神经生长因子（NGF）的存在，通过抑制类胡萝卜素样蛋白（CNPY2/MSAP）稳定MRLC，并减少CNPY2刺激的轴突生长。通过介导泛素化和随后的LDLR降解，作为甾醇依赖的细胞胆固醇摄取抑制剂。